Article

Endocrine Month in Review: April 2022

Most Popular Stories of April 2022

1. Racial/Ethnic Disparities in Eye Care for Patients with Diabetes

  • A University of Houston College of Pharmacy-led analysis of US Medical Expenditure Panel Survey data from 2009-2018 sought to assess racial/ethnic disparities in eye care for patients with diabetes.
  • In adjusted models, Hispanic and African American patients were 1.63 and 1.61 times more likely to have diabetic eye complications compared to their White counterparts and African American patients were 29% less likely to complete all of the ADA-recommended processes of diabetes care.

2. Role of CGM in Diabetes Management

  • In a recent edition of EndoView, Dr. Diana Isaacs reviews the role of CGM in diabetes management and shares considerations for the utilization and impact of CGMs in the diabetes treatment landscape.
  • Launched on April 7, the multipart series touches on emerging systems, the evolution of CGM, and patient factors when choosing a CGM system.

3. PFAS Exposure and Diabetes During Midlife in Women

  • An analysis of SWAN-MPS led by investigators at Michigan Medicine assessed associations of PFAS exposure with risk of T2D in midlife among women.
  • The 1200-woman analysis suggested women in the highest tertile of PFAS exposure were at a more than 2-fold increase in risk of developing incident diabetes compared to their counterparts in the lowest tertile of exposure.

4. Switching from MDI to AHCL Improves Glycemic Control

  • A prospective, open-label, single-arm study assessed the effects of switching from multiple daily injections to an advanced hybrid closed loop system in patients with type 1 diabetes.
  • Results indicated TIR increased from 42.1±18.7% at baseline to 78.8±6.1% in the study phase (P <.001), with mean HbA1c decreasing from 8.6±1.7% at baseline to 6.5±0.7% at the end of the study (P=.001), with no episodes of severe hypoglycemia or diabetic ketoacidosis reported during the study.

5. NSAID Use Inhibits Bisphosphonate Benefit

  • A prospective, open-label, single-arm study assessed the effects of switching from multiple daily injections to an advanced hybrid closed loop system in patients with type 1 diabetes.
  • Results indicated TIR increased from 42.1±18.7% at baseline to 78.8±6.1% in the study phase (P <.001), with mean HbA1c decreasing from 8.6±1.7% at baseline to 6.5±0.7% at the end of the study (P=.001), with no episodes of severe hypoglycemia or diabetic ketoacidosis reported during the study.

6. Prediabetes Column from Dr. Gregory Weiss

  • A recent report from the CDC and a study published in the Journal of General Internal Medicine underline the concern growing around the rising rate of prediabetes in the US.
  • In this column, Dr. Gregory Weiss discusses the importance and practicality of current screening efforts for diabetes.

7. Study Estimates Life-Years Added from Meeting T2D Treatment Goals

  • Using a diabetes-specific microsimulation model and data from NHANES, a team from University of Florida College of Pharmacy sought to assess life years added from achieving treatment goals in T2D.
  • Results of the study suggested those in the lowest population quartile for BMI, HbA1c, systolic blood pressure, and LDL-C experience life expectancy gains of 3.9, 3.8, 1.9, and 0.9 years, respectively, when compared to their counterparts in the highest quartile for each category.

Related Videos
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
© 2024 MJH Life Sciences

All rights reserved.